logo

Review Timeline | CrossMark Policy | ClinMed Features
   

Need a supporting hand in manuscript formatting? Write to our team.
Assistance in presubmission | editorialoffice@clinmedjournals.org

     
Journal of
Genetics and Genome Research
ISSN: 2378-3648
RESEARCH ARTICLE | VOLUME 4, ISSUE 1 | OPEN ACCESS DOI: 10.23937/2378-3648/1410029

Testing the Mutagenicity Potential of Chemicals

Geert R Verheyen , Koen Van Deun and Sabine Van Miert

Thomas More University College, Belgium

*Corresponding author: Geert R Verheyen, Radius, Thomas More University College Campus Geel, Kleinhoefstraat 4, 2440 Geel, Belgium, Tel: +32-0-14-562310, E-mail: geert.verheyen@thomasmore.be

Received: June 18, 2016 | Accepted: May 13, 2017 | Published: May 15, 2017

Citation: Verheyen GR, Deun KV, Miert SV (2017) Testing the Mutagenicity Potential of Chemicals. J Genet Genome Res 4:029. doi.org/10.23937/2378-3648/1410029

Copyright: © 2017 Verheyen GR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract


All information for the proper development, functioning and reproduction of organisms is coded in the sequence of matched base-pairs of DNA. DNA mutations can result in harmful effects and play a role in genetic disorders and cancer. As mutations can arise through exposure to chemical substances, testing needs to be done on substances that humans and animals can be exposed to. This review focuses on the different testing strategies for risk assessment of chemicals for genotoxicity and carcinogenicity. This review is not meant to cover all testing methodologies, but rather to give an overview of the main methodologies that are used in a regulatory context. In silico and in vitro tools are playing an increasingly important role, in order to reduce in vivo animal testing. Especially in silico tools like (Q)SARs are promising as they are non-testing methods and thereby also reduce the costs and time that are needed to perform in vitro assays. (Q)SARs are not sufficiently reliable to be used as stand-alone tools, and should be associated with expert judgment or used in combination with other Weight of Evidence such as in vitro and in vivo data and data derived from other similar molecules (read-across). For some product (sub) categories, testing (in vitro/in vivo) will be unavoidable; however the future may bring reliable approaches for ensuring human safety.

Keywords


Mutagenicity, In vivo, In vitro, QSAR, Hazard identification, Risk assessment

Introduction


The genetic make-up of all organisms is contained within the double helix of DNA. All information for the development, functioning and reproduction of organisms is coded within the sequence of matched base-pairs and it is of crucial importance that this information is passed on to progeny without or with the least amount of error possible. Thus at the cellular level it is important that the replication of DNA and the segregation of the fully replicated DNA molecules to the 2 daughter cells occurs accurately. However, DNA replication is not a faultless process and mutations, which can be defined as various types of permanent changes in DNA, do occur in all organisms. Mechanisms underlying mutations have been well studied and are described in many textbooks [1]. Whether mutations will affect gene function depends on where they occur within a gene or whether they affect levels of gene expression, mRNA splicing or protein composition. About 70% of the mutations that result in an amino acid change in a protein is estimated to be harmful [2].

A first type of mutation occurs due to the incorporation of a wrong base during replication. This can occur spontaneously or can be chemically induced and will result in a mismatch between base pairs. If this is not repaired, it will lead to a mutation in the next round of replication. Misincorporations lead to transitions in which a pyrimidine is changed into the other pyrimidine or a purine into the other purine and to transversions in which a pyrimidine is changed into a purine or vice versa.

Other types of mutations include insertions or deletions of 1 or more base pairs into the DNA sequence. Mutations can also involve amplifications or deletions of large chromosomal areas leading to multiple copies or loss of the genes located within this region, respectively [3]. These complex mutations are caused by chromosomal translocations, interstitial deletions and chromosomal inversions and can also result in juxtaposition of previously separate pieces of DNA, potentially even forming functionally distinct fusion genes, with potential harmful effect.

Finally, during mitosis or meiosis, large chromosomal pieces or even whole chromosomes may be lost during the formation of daughter cells due to missegregation events or chromosome breakage. This may also result in the loss or increase in number of alleles of genes, with deleterious effects for the organism. These types of genotoxicants are non-mutagenic and they may have threshold mechanisms. Typical examples are topisomerase II poisons or mechanisms based on reactive oxygen species; other mechanisms may lead to aneuploidy [4-6].

DNA damage introduced by endogenous and exogenous sources continuously threatens the structure and integrity of DNA molecules. Due to the deleterious effects that mutations can have on the functioning of gene products, organisms have evolved complex DNA repair mechanisms that are aimed to prevent or correct mutations by reverting the mutated sequence back to its original state before they are fixed as permanent genetic changes [7]. If DNA lesions remain unrepaired or if they are erroneously repaired, they will most probably hamper crucial cellular processes like transcription and replication, which may result in cell cycle arrest and possibly (programmed) cell death. However, potentially the mutation may become fixed. At the level of the organism, mutations in germ cells can result in genetically inherited diseases, while accumulation of mutations in somatic cells is associated with the initiation and progression of cancer. DNA damage is also believed to be involved in aging [8].

Mutations and Pathogenesis


In this short overview paper we focus on the implications of mutations for humans. The importance of DNA and the impact of mutations and chromosomal aberrations for human health are clear from their observed roles in numerous genetic diseases and cancer. Therefore potential for mutations in both somatic and germs cells need to be taken into account when an overall risk estimate resulting from mutations is concerned [9].

Many genetic disorders (e.g. cystic fibrosis) are recessive in nature, indicating that the underlying mutations are expressed when an affected individual inherits the mutated gene from both parents. Disorders showing a dominant inheritance pattern require only 1 copy of the mutated gene in order to become expressed in the affected individual. For dominant genetic disorders a single mutation is sufficient for disease expression, and therefore new mutations make a larger contribution to the incidence of dominant diseases [9]. However, the occurrence of a mutation can be obscured by incomplete penetrance of the affected phenotype.

Structural chromosome aberrations can cause miscarriage and fetal death or serious abnormalities [10]. Aneuploidy, which is defined as the gain or loss of one or more chromosomes contributes to perinatal death, but also causes disorders such as trisomy 21. The majority of chromosomal abnormalities result from trisomies and occur prenatally [11]. As exposure of the developing infants to specific chemicals has been shown to induce birth defects, it is important to sufficiently screens new compounds for potential teratogenic effects prior to release to the market [12].

The correlation between the mutagenicity and carcinogenicity of chemicals has long been evident [13]. Another demonstration of this association is presented by the correlation of human chromosome instability syndromes and DNA repair deficiencies, with increased cancer risks [14]. Molecular studies of so-called proto-oncogenes and tumor suppressor genes have also shown that mutations play an important role in the processes leading to cancer. These genes encode for proteins that typically help to control cell growth and proliferation. Proto-oncogenes (e.g. ras) can be converted into active oncogenes by point mutations [15] or chromosomal aberrations, and subsequently stimulate the transformation of normal cells into cancer cells [16]. A tumor suppressor gene (e.g. p53) typically protects a cell by inhibiting cell proliferation and tumor development, and mutational inactivation or deletion of these genes have been implicated in human tumors [17]. Many cancers involve both activation of oncogenes and inactivation of tumor suppressor genes, as well as other possible events. This implies that carcinogenesis is a multistep process resulting from an accumulation of genetic alterations [18-20].

Hazard assessment for genetic toxicity is done by means of testing and non-testing methods as will be discussed in this overview. Also available human data is important for hazard assessment. This is closely related to the hazard assessment for carcinogenicity, at least for genotoxic carcinogens.

Non-genotoxic carcinogens, will not be positive in genotoxicity studies because they act via other mechanisms (e.g. peroxisome proliferator-induced hepatocarcinogenesis in rodents; [21] and thus need other testing methods. However this is out of scope of this review.

Risk assessment for genotoxicity is not as easily performed as for carcinogenicity. The usual approach is to combine rodent germ and somatic cell data for induced genetic alterations with human somatic cell data (if available) in order to estimate the frequency of mutations in human cells. For a complete estimate of genetic risk, it is then necessary to obtain an estimate of the frequency of genetic alterations that are transmitted to the offspring [22].

Chemical Mutagens and Classification


Reactive chemicals that can induce covalent bond formation with endogenous molecules such as DNA can act as a rate determining step in mutagenesis. These types of reactive chemicals can sometimes also affect other human health endpoints such as skin sensitization and target organ toxicity. Reactive chemicals are characterized by the presence of electrophilic groups that can react with nucleophilic sites in DNA or proteins. Some examples of typical substances causing DNA binding are alpha, beta unsaturated aldehydes, hydrazines, nitrogen mustard and polyaromatic hydrocarbons [23]. The representative nucleophilic sites in DNA are the bases guanine, adenine, thymine, and cytosine, whereas in proteins the amino acids, lysine, histidine, and tyrosine show most nucleophilic activity [24]. Schultz, et al. [25] described a conceptual framework for predicting the toxicity of reactive chemicals for which the initiating events were based on covalent reactions with nucleophiles in proteins or DNA and that could lead to a variety of different adverse outcomes, including mutagenicity and sensitisation, but also target organ toxicity such as hepatocyte cytoxicity or respiratory toxicity. These measures of intrinsic reactivity are suitable to be modelled as endpoints for QSARs rather than the toxicity endpoints that they reflect [25].

Classification of chemicals for germ cell mutagenicity can be done according to the latest 'CLP' European classification system [26]. Based on the classification, manufacturers have to label their substances and take appropriate technical and personal protective measures for their workers. Classification for germ cell mutagenicity may also trigger the Regulatory Authorities such as ECHA and Member States to list and evaluate the substance as a very high concern substance. 'Category 1' mutagens are substances that are known to induce heritable mutations or that are to be regarded as if they can induce heritable mutations in human germ cells. These substances can be further classified into sub-class 1A (classification based on positive human epidemiological studies) or 1B, if the classification is based on positive results from testing. The positive test results can be from (1) In vivo heritable germ cell mutagenicity tests in mammals; (2) In vivo somatic cell mutagenicity tests in mammals, in combination with other evidence that the substance has potential to cause mutations to germ cells; or (3) From data showing mutagenic effects in human germ cells, without demonstration of transmission to progeny (e.g. increased aneuploidy in sperm cells of exposed people).

Substances are classified as 'Category 2' mutagens if there is concern that the substance may induce heritable mutations in human germ cells. The concern can be based on positive evidence that is obtained from animal experiments and/or sometimes from in vitro experiments in somatic cells. Substances that are positive in in vitro mammalian mutagenicity assays, and that also show chemical structure activity relationships to known germ cell mutagens, will also be considered for classification as Category 2 mutagens.

According to latest Guidance on classification of chemicals [27], the classification of individual substances shall be based on the total weight of evidence available, using expert judgement. A single, well-conducted test may be used for classification if it gives clear and unambiguously positive results. Newly developed and validated tests may also be used in the total weight of evidence. The relevance of the route of exposure used in the study compared to the most likely route for human exposure is also taken into account [27]. When there is only evidence of somatic cell genotoxicity, it is also warranted that the substance is also regarded as suspected germ cell mutagen. Classification as a suspected germ cell mutagen may also have implications for potential carcinogenicity classification. This also holds true for genotoxicants which are incapable of causing heritable mutations, because they act locally and cannot reach the germ cells. This implies that if positive results in vitro are supported by at least one positive local in vivo, somatic cell test, that this is considered as enough evidence to lead to Category 2 classification. If there is also negative or equivocal data available, a weight of evidence approach using expert judgement has to be applied [27].

Testing for Mutagenicity Potential According to Regulatory Context


For regulatory purpose, the mutagenicity potential of a chemical has mainly been evaluated using in vitro assays, in particular the Bacterial Reverse Mutation Test [28] and the Mammalian Cell Gene Mutation Assay [29], as described in Table 1.

Table 1: Major in vitro and in vivo testing models for mutation. View Table 1

The Ames test is a short-term bacterial reverse mutation assay that is designed to detect a wide range of chemical substances that can produce genetic damage that leads to gene mutations. In this assay, mutations present in bacterial test strains are reverted in the presence of mutagenic agents, thereby restoring the functional capability of the bacteria to synthesize an essential amino acid (histidine) and to grow colonies [30]. This assay detects point mutations, including substitution, addition or deletion of one or a few DNA base. Different Salmonella strains are used that have different mutations in the histidine operon, each of which is designed to be responsive to mutagens that act via different mechanisms [28]. Over the years, several modifications of the test have been done in order to increase the number of applications possible and in order to allow a testing of a wider range of chemicals (including gases,..). The assay is rapid, inexpensive and relatively easy to perform. However the test utilises prokaryotic cells, which differ from mammalian cells in such factors as uptake, metabolism, chromosome structure and DNA repair processes. An exogenous source of metabolic activation (e.g. Arochlor 1254 induced rat liver S-9 fraction) is therefore commonly used as well, but such systems cannot entirely mimic the mammalian in vivo conditions. The test is typically employed as an initial screen for genotoxic activity and, in particular, for point mutation-inducing activity [31,32]; Gatehouse, et al., 1994) [31-33]. It is widely accepted that positive results in the Ames test correlate well with carcinogenic potential, at least in rodents (70-90% predictivity; [28]. In certain situations the mutagenic response may be specific to the bacterial test and therefore be false positive [34,35].

The mammalian cell gene mutation test applies mammalian cell lines such as (L5178Y) mouse lymphoma cells, CHO AS52 and V79 lines of Chinese hamster cells, and TK6 human lymphoblastoid cells. In these cell lines 'forward' mutations are typically measured at the thymidine kinase (TK) locus and hypoxanthine-guanine phosphoribosyl transferase (HPRT) locus, and at a transgene of xanthineguanine phosphoribosyl transferase (XPRT) locus. The TK, HPRT and XPRT mutation tests detect different spectra of genetic events, because the autosomal location of TK and XPRT may allow the detection of genetic events (e.g. large deletions) that are not detected at the X-linked HPRT locus [36]. These tests are used to screen for possible mammalian mutagens and carcinogens and thus complement the bacterial mutation assays. Many compounds that are positive in these tests are mammalian carcinogens, however, also in this case, the correlation is not perfect [37].

If there is a positive result in any of the in vitro genotoxicity studies and there are no results available from an in vivo study, an appropriate in vivo somatic cell genotoxicity study should be performed to exclude or confirm the potential mutagenicity for humans. For chemicals, these information requirements are described [38]. If there is a positive result from an in vivo somatic cell study available, the potential for germ cell mutagenicity should be further investigated.

Testing for chromosome damage potential has traditionally been evaluated using in vivo assays such as the chromosome aberration and micronucleus test methods. However it has been demonstrated that these in vivo methods can be replaced by in vitro assays, as described in Table 2.

Table 2: Major in vivo and in vitro testing models for chromosome damage. View Table 2

The in vivo mammalian chromosome aberration test is used to detect structural chromosome aberrations that are induced by test compounds in bone marrow cells of rats, mice or Chinese hamsters [39]. While the majority of genotoxic chemical-induced aberrations are of the chromatid-type, chromosome-type aberrations also occur. Chromosomal damage and related events are the cause of many human genetic diseases and there is substantial evidence that, when they cause alterations in oncogenes and tumour suppressor genes, they are involved in cancer [40-43]. The in vitro chromosome aberration test is used to identify agents that cause structural chromosome aberrations in cultured mammalian somatic cells [44] and is usually performed with and without metabolic activation of the test substance. Both in vivo and in vitro chromosome aberration tests are not designed to measure aneuploidy.

In the micronucleus assay, chromosome fragments (induced by chromosome breaks) and whole chromosomes (occurring due to faults in the segregation of chromosomes to daughter cells) can be detected as an extra cytoplasmic body. Subsequent to the effect induced by the substance, a chromosome fragment or a whole chromosome will become visible as a small nucleus. The micronucleus assay is thus capable of detecting clastogenic (chromosome breakage) as well as aneugenic substances. Using fluorescence in situ hybridisation methods or flow cytometry techniques clastogenic and aneugenic actions can be discerned. Several forms of micronucleus assays (mononucleate and binucleate assays) have been developed [45]. The in vivo mammalian micronucleus test is used to detect cytogenetic damage induced by test substances to the chromosomes or the mitotic apparatus of erythroblasts, sampled in bone marrow or peripheral blood of mice or rats [46]. When a bone marrow erythroblast develops into a polychromatic erythrocyte or reticulocyte, the main nucleus is extruded; however, any micronucleus that has been formed will remain behind in the cytoplasm and can be scored. An increase in the frequency of micronucleated immature erythrocytes is an indication of induced structural and/or numerical chromosomal aberrations. Visual scoring by a microscope can be easily automated, which is also a big advantage of this assay [47]. The in vitro Micronucleus Test (MNvit) also detects micronuclei in the cytoplasm of interphase cells that have undergone cell division during or after exposure to a test substance [48]. Several cells such as human lymphocytes and Syrian hamster embryo cells, and cell lines (CHO, V79, L5178Y,...) are typically used. Also here different methodologies can be performed with and without metabolic activation of the test substance [6]. In the micronucleus assay, the slides can be scored relatively quickly and analysis can also be automated, which makes it practical to score thousands instead of hundreds of cells per treatment, increasing the power of the test.

Other assays are sometimes used for testing for (1) DNA damage and repair [49,50] guidelines for the Unscheduled DNA Synthesis (UDS) test in vitro and in vivo, (2) For measuring DNA strand breaks in eukaryotic cells [51] guidelines for the in vivo Mammalian Alkaline Comet Assay and (3) For demonstration of germ cell gene mutation (Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays). These assays have been relatively frequently been used in the past, but are nowadays typically used in situations in which an additional assay is needed to help to resolve a potential mutagenicity issue of a substance.

An in vivo assay with potential for regulatory safety assessment is the Pig-A gene mutation assay [52]. This assay is capable of measuring in vivo gene mutations at the Pig-A gene, which cause failure of 'GPI anchors', resulting in the absence of specific surface markers on the exterior of peripheral blood cells. Using flow cytometry the frequency of cells without these surface makers is easily performed, requiring only microliter volumes of blood. Other existing and modified in vitro assays like the more high throughput Ames II assay [53], the Vitotox assay [54], can be used for specific purposes, however the discussion of all possible models is beyond the scope of this work.

For pharmaceutical development, an initial test battery is needed that comprises the bacterial reverse mutation (e.g. Ames) test and an in vitro test either for chromosomal damage or for mammalian gene mutation (e.g. Mouse Lymphoma TK assay). In addition, an in vivo test using rodent hematopoietic cells, either for detection of micronuclei or for chromosomal aberrations in metaphase cells is required [55]. Proposals have been made that an in vitro genotoxicity testing core battery should be sufficient by a combination of the Ames test and the in vitro micronucleus test (MNvit), since the latter assay detects both chromosomal aberrations and aneuploidy [56].

For chemicals, the requirements on mutagenicity are described by REACH (Annexes VI-XI) that specifies the information per tonnage band that must be submitted for registration and evaluation purposes. The bacterial reverse mutation (Ames) test is the basic requirement from 1 tonne/year onwards, followed by an in vitro chromosome aberration study in mammalian cells or an in vitro micronucleus study for substances from 10 tonnes/year onwards. If these studies are negative, an additional in vitro gene mutation study in mammalian cells is required for chemicals from 10 tonnes/year onwards. Only for the higher tonnage bands of 100 and 1000 tonnes/year, an in vivo somatic cell genotoxicity study may have to be provided by the registrant if there is a positive in vitro study, to clear out the results [38].

In silico Assessment of Mutagenicity Potential


A next evolution in the mutagenicity assessment of compounds is the use of in silico methods. These are mainly (quantitative) structure activity relationship models and expert systems that combine physic-chemical or structural properties (descriptors) and computational tools to assign a substance to a certain category or biological/toxicological activity. In other words, based on chemical class or mechanistic reactivity domain, substances can predicted positive or negative for a certain toxicological endpoint (e.g. skin sensitisation, acute toxicity, mutagenicity,...).

The results of validated (Q)SARs and expert judgement may also be taken into account for classification and labelling. To support the self-classification process for companies to meet their obligation to self-classify the chemicals they import or produce, the Danish EPA published an advisory list for self-classification of dangerous substances [57]. The list of suggested hazard classifications was derived from (Q)SAR prediction models (obtained or developed by the Danish EPA) for various endpoints, including mutagenicity. The (Q)SAR models were used to make predictions for the numerous discrete organic substances in the EINECS, and the updated Danish Advisory List contains the results of a systematic assessment of 49292 discrete organic substances [57].

(Q)SAR models can either include expert knowledge (e.g., Derek nexus, Toxtree) or be fully based on the statistical evaluation of structure fragments determined in a model training set (e.g., CASE Ultra, VEGA, TOPKAT). There is also the OECD (Q)SAR toolbox, which provides mechanistic information along the adverse outcome pathway from which substance-specific (Q)SAR models can be created [58].

In Table 3, the two main types of models are described by means of some examples, however more models are available. Models are either mechanism- (or rule-) based or they are derived empirically using statistical approaches. Some molecules may not fall into the specified applicability domain of the (Q)SAR models. If that happens, the predictions are unreliable and other (Q)SARs or different approaches need to be applied to predict the mutagenicity, chromosome aberration or carcinogenicity potential.

Table 3: Examples of in silico models for mutagenicity. View Table 3

A large experimental Ames assay mutagenicity data set, comprising about 6500 non-confidential compounds, was compiled and made publicly available [59]. A comparison was done of the predictive performance of three commercial software packages (Derek, MultiCASE, and an off-the-shelf Bayesian machine learner in Pipeline Pilot) with four non-commercial machine learning implementation tools (Support Vector Machines, Random Forests, k-Nearest Neighbours, and Gaussian Processes). In this evaluation, Pipeline Pilot, trained on the developed Ames data set, showed the best predictivity of the three commercial tools followed by MultiCASE. The expert system Derek gave the lowest sensitivity and specificity of all considered models. However, closer examination of the results revealed that the difference in sensitivity between the best commercial model and the best non-commercial machine learning approach is just a few percent, making it difficult to draw conclusions regarding robustness of the software tools. In general, machine learning algorithms are expected to perform better in cases such as this, because they draw their knowledge exclusively from the training data, as opposed to models such as Derek, which has rules derived from other datasets or based on expert knowledge. This study was very useful in terms of the mutagenicity dataset which was made publicly available, but also because it demonstrates the power of machine learning approaches for model discovery and development.

For pharmaceutical impurities, hazard assessment also involves an initial analysis of actual and potential impurities by conducting database and literature searches for carcinogenicity and bacterial mutagenicity data. If such data are not available, a (Q)SAR assessment that focuses on bacterial mutagenicity prediction should be performed. Two (Q)SAR prediction methodologies, one expert rule-based and one statistical-based, that complement each other should be applied [60]. (Q)SAR models utilizing these prediction methodologies should follow the general validation principles that are set forth by the Organisation for Economic Co-operation and Development (OECD). In the case that the two complementary (Q)SAR methodologies indicate that structural alerts for mutagenicity are absent, it is sufficient to conclude that the impurity is not of mutagenic concern, and that no further testing is needed. If warranted, the outcome of any computer system-based analysis can be supplemented with additional expert knowledge in order to increase the supportive evidence on relevance of any positive, negative, conflicting or inconclusive prediction and to provide a rationale to support the final conclusion [60]. A (Q)SAR assessment for chromosomal aberration or carcinogenicity is not required. The focus is on DNA reactive substances causing DNA damage and mutations and possibly when present at low levels. Other types of genotoxicants that are non-mutagenic typically have threshold mechanisms and usually do not pose carcinogenic risk in humans at the level ordinarily present as impurities.

For chemicals, non-testing (i.e. not performing in vitro or in vivo experiments) information about the mutagenicity can be used as weight-of-evidence in a variety of ways, ranging from simple inspection of the chemical structure through read-across techniques, expert systems, metabolic simulators, or (Q)SARs. Generally, (Q)SAR models that contain putative mechanistic descriptors are preferred. Predictivity must be assessed case-by-case on the basis of clear documentation and a QSAR Model Reporting Format (QMRF) and a QSAR Prediction Reporting Format (QPRF) have been developed by the Joint Research Centre (JRC) of the European Commission to ensure consistency in summarising and reporting key information on (Q)SAR models and substance specific predictions generated by (Q)SAR models [38].

Reliability of (Q)SAR Applications for Mutagenicity Prediction


Many investigations have focused on the ability of computational models to accurately predict the mutagenic effects of a chemical in the Ames assay, either individually or in combination [61]. Typically for these investigations, large numbers of compounds are evaluated with different in silico tools to predict their mutagenic potential, with no human interpretation being made. The use of multiple models in consensus to enhance prediction is also widely accepted [62]. However, this does not indicate how these assessments are effectively conducted in practice across the (pharmaceutical) industry.

Eight companies were surveyed for their success rate in prediction of mutagenicity with in silico tools [63]. The Negative Predictive Value (NPV) of the in silico approaches was 94%. When human interpretation of in silico model predictions was conducted, the NPV increased substantially to 99%. The survey clearly illustrated the importance of expert interpretation of in silico predictions. In addition, the survey also suggested that the use of multiple computational models is not a significant factor in the success of the in silico approaches with respect to NPV [63]. A new tool that can help in the (in silico) interpretation of mutagenicity of a chemical is the ToxRead software [64]. ToxRead attempts to standardize the read across process using ad hoc visualization and data search methods. Based on similarity measures and fragment searches, the software constructs a picture that contains all relevant information that is useful to make an assessment of the mutagenic potential of the substance. In this picture the substance under evaluation is compared to similar compounds, which are known to be mutagenic or not. Structural alerts that are linked to the evaluated chemical are also included in the picture, thereby summarizing a lot of information into a picture. By clicking structural alerts and compounds in the picture, additional information can be obtained in tabular form.

An evaluation of (Q)SAR models for the prediction of mutagenicity (and carcinogenicity) was performed by [65] for models for congeneric chemical classes and structure alert (SA) models. QSARs that estimated the potency of congeneric chemicals were 30% to 70% correct, when evaluating chemicals that were not considered by the developers of the models. The models that discriminated active and inactive chemicals were considerably more accurate (70% to 100%). It was shown that the internal cross-validation statistics were poorly correlated with external validation statistics using chemicals that were not part of the initial dataset used for constructing the QSAR. The genotoxic-based SA models had an accuracy of about 75% for Salmonella mutagens. However, the SA models were not able to discriminate active and inactive chemicals within individual chemical classes well and they seem better suited for preliminary or large-scale screenings. Overall it was concluded that the (Q)SAR-based tools are not meant to be black-box machines for predictions, but that they can play an important role. QSARs are able to significantly enrich for safer chemicals, contribute to the organization and rationalization of data, elucidate mechanisms of action, and complement data that is derived from other sources [65].

The FDA's 2008 draft guidance on genotoxic and carcinogenic impurities in drug substances and products allows the use of QSARs to identify structural alerts for known and expected impurities present at levels below qualified thresholds [66]. A Leadscope model predicting Salmonella t. mutagenicity (Ames assay) of drug impurities and other chemicals was described for regulatory use. A high sensitivity (81%) and high negative predictivity (81%) was obtained, based on external validation with 2368 compounds foreign to the model and having known mutagenicity. A database of drug impurities was created from proprietary FDA submissions and from the public literature, which found a significant overlap between the structural features of drug impurities and training set chemicals in the QSAR model. The predictive performance of the model was found to be acceptable for screening drug impurities for Salmonella mutagenicity [66].

For evaluation of impurities in drug substances and products, computational toxicology assessment should be performed using (Q)SAR methodologies that predict the outcome of a bacterial mutagenicity assay [67]. Two (Q)SAR prediction methodologies that complement each other should be applied, one methodology should be expert rule-based and the second should be statistical-based. The absence of structural alerts for mutagenicity from two complementary (Q)SAR methodologies is sufficient to conclude that the impurity is of no mutagenic concern, and that no further testing is recommended. If warranted, the outcome of any computer system-based analysis can be reviewed with the use of expert knowledge (including for example the use of tools like ToxRead) in order to provide additional supportive evidence on relevance of any positive, negative, conflicting or inconclusive prediction and provide a rationale to support a final conclusion [60].

The performance of public (Q)SAR models predicting Ames genotoxicity was further assessed for a selection of chemicals registered under REACH regulation [68]. The Benigni/Bossa rule base originally implemented in ToxTree and re-implemented within VEGA displayed the best performance (accuracy = 92%, sensitivity = 83%, specificity = 93%, MCC = 0.68) indicating that this rule base provides a reliable tool for the identification of genotoxic chemicals.

Further Evolutions


Various initiatives are being taken to integrate (Q)SAR methods with other Weight of Evidence. A ChemTunes prediction system was implemented by the Chemical Evaluation and Risk Estimation System (CERES) at the U.S. FDA's Office of Food Additive Safety (OFAS) for review and monitoring of food ingredients and packaging materials. The system allows access to expansive, reliable experimental data, and predicts results based on both expert knowledge and mode-of-action driven QSAR models. The prediction results from local and global models as well as chemotype rules (alerts) are combined to predict the outcome while minimizing the overall uncertainty [69]. When tested on a more extensive databased of 3950 compounds, validation results showed an average negative predictive value (NPV) of 92.6% [70].

Another study was performed to combine QSAR data with literature on carcinogenic modes of action automatically generated by a text-mining tool. A group so 96 rat carcinogens pointed out that skin and lung rat carcinogens were mainly mutagenic, whereas hematopoietic and liver carcinogens included a large proportion of non-mutagens. Mechanisms such as immunosuppression and hormonal receptor-mediated effects were involved. The method can be particularly useful in increasing the understanding of structure and activity relationships for non-mutagens [71].

Final Conclusions


Genotoxicity hazard identification and risk assessment is important to assure the safety of substances that humans can be exposed to. Several implemented testing methods that are routinely performed have been reviewed here. This review is not meant to be complete and covering all testing methodologies, but rather to give an overview of main methodologies (in silico, in vitro and in vivo) that are used for a regulatory context.

In order to reduce the number of animals sacrified for testing of the numerous numbers of chemical substances that need better characterisation for their mutagenic potential, in silico and in vitro are playing an increasingly important role. Especially in silico tools like QSARs are promising as they are non-testing methods, thereby reducing cost and time to perform in vitro assays. However, more work on improving reliability of these non-testing tools needs to be done in order for them to become fully accepted alternatives. (Q)SARs are not meant as stand-alone tools; they should be done either in a battery of different (rule- and statistically based) QSAR models, associated with expert judgment or in combination with other Weight of Evidence (WoE) such as in vitro data and in vivo data from other similar molecules (read-across). In this context, they can be used more and more for various product categories as an integrated testing strategy (ITS) in order to avoid and replace animal testing. For some product (sub) categories such as pharmaceuticals and chemicals, testing (in vitro/in vivo) will be unavoidable, however future may bring more reliable approaches for ensuring human safety. For other product types, such as impurities, a combination of (Q)SARs for bacterial mutagenicity is acceptable to assess potential genotoxic impurities if no data are available. Newer models also integrate more Weight of Evidence information, either by means of literature data or mechanism of action.

References


  1. Strachan T Read, Sutter A (2010) Human Molecular Genetics. (4th edn). Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul Toxicol Pharmacol 67: 39-52.

  2. Sawyer SA, Parsch J, Zhang Z, Hartl DL (2007) Prevalence of positive selection among nearly neutral amino acid replacements in Drosophila. Proc Natl Acad Sci U S A 104: 6504-6510.

  3. PJ Hastings, James R Lupski, Susan M Rosenberg, Grzegorz Ira (2009) Mechanisms of change in gene copy number. Nat Rev Genet 10: 551-564

  4. Bolt HM, Degen GH (2004) Degen Human Carcinogenic Risk Evaluation, Part II: Contributions of the EUROTOX Specialty Section for Carcinogenesis. Toxicol Sci 81: 3-6.

  5. Heidi Foth, Gisela H Degen, Hermann M Bolt (2005) New aspects in the classification of carcinogens. Arh Hig Rada Toksikol 56: 167-175.

  6. Kirsch-Volders M, Decordier I, Elhajouji A, Plas G, Aardema MJ, et al. (2011) In vitro genotoxicity testing using the micronucleus assay in cell lines human lymphocytes and 3D human skin models. Mutagenesis 26: 177-184.

  7. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85.

  8. Holmes GE, Berstein C, Bernstein H (1992) Oxidative and other DNA damages as the basis of aging a review. Mutat Res 275: 305-315.

  9. Preston RJ, Hofmann GR (2008) Genetic Toxicology. In: C D Klaassen Casarett, Doull's, Toxicology The Basic Science of Poisons. (7th edn), McGraw Hill Medical, Kansas City, USA, 381-413.

  10. Kochkar PK, Ghosh P (2013) Reproductive outcome of couples with recurrent miscarriage and balanced chromosomal abnormalities. J Obstet Gynaecol Res 39: 113-120.

  11. NRC (National Research Council) (1990) Committee on the Biological Effects of Ionizing Radiations Health Effects of Exposure to Low Levels of Ionizing Radiation. BEIRV, Washington DC.

  12. Vargesson N (2015) Thalidomide-induced teratogenesis history and mechanisms. Birth Defects Res C Embryo Today 105: 140-156.

  13. Ashby J, Tennant RW (1991) Definitive relationships among chemical structure carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. Mutat Res 257: 229-306.

  14. Friedberg EC (1985) DNA Repair. New York, Freeman.

  15. Barret JC (1993) Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Prospect 100: 9-20.

  16. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64: 235-248.

  17. Feng Z, Hu W, Rajagopal R, Levine AJ (2008) The tumor suppressor p53 cancer and aging. Cell Cycle 7: 842-847.

  18. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.

  19. Marshall CJ (1991) Tumor supporessor genes. Cell 64: 313-326.

  20. Carnero A, Blanco-Aparicio C, Kondoh H, Lleonart ME, Martinez-Leal JF, et al. (2015) Disruptive chemicals senescence and immortality. Carcinogenesis 36: S19-S37.

  21. MS Rao, Jk Reddy (1991) An overview of peroxisome proliferator-induced hepatocarcinogenesis. Environ Health Perspect 93: 205-209

  22. UNSCEAR (United NATIONS Scientific Committee on the Effects of Atomic Radiation) (2001) Report to the General Assembly, with Scientific Annex. Hereditary Effects of Radiation, United Nations, New York.

  23. Poirier MC (2012) Chemical-induced DNA damage and human cancer risk. Discov Med 14: 283-288.

  24. Mekenyan O, Patlewicz G, Dimitrova G, Kuseva C, Todorov M, et al. (2010) Use of Genotoxicity Information in the development of Integrated Testing Strategies (ITS) for Skin Sensitization. Chem Res Toxicol 23: 1519-1540.

  25. Schultz TW, Carlson RE, Cronin MT, Hermens JL, Johnson R, et al. (2006) A conceptual framework for predicting the toxicity of reactive chemicals modeling soft electrophilicity. SAR QSAR Environ Res 17: 413-428

  26. CLP regulation (ec) no 1272/2008 of the European parliament and of the council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing.

  27. ECHA - European Chemicals Agency (2013) Guidance on the Application of the CLP Criteria. Guidance to Regulation (EC) No 1272/2008 on classification, labelling and packaging (CLP) of substances and mixtures, Version 4.0.

  28. Mortelmans K, Zeiger E (2000) The Ames Salmonella/microsome mutagenicity assay. Mutat Res 455: 29-60.

  29. Johnson GE (2012) Mammalian cell HPRT gene mutation assay: test methods. Methods Mol Biol 817: 55-67.

  30. (1997) OECD Guideline for the testing of chemicals Bacterial Reverse Mutation. Guideline for the testing of chemicals. In Vitro Mammalian Chromosome Aberration Test.

  31. Ames BN, McCann J, Yamasaki E (1975) Methods for detecting carcinogens and mutagens with the salmonella mammalian-microsome mutagenicity test. Mutat Res 31: 347-364.

  32. Maron DM, Ames BN (1983) Revised Methods for the Salmonella mutagenicity Test. Mutat Res 113: 173-215.

  33. Gatehouse D, Haworth S, Cebula T, Gocke E, Kier L, et al. (1994) Recommendations for the Performance of Bacterial Mutation Assays. Mutat Res 312: 217-233.

  34. McCann J, Choi E, Yamasaki E, Ames BN (1975) Detection of carcinogens in the Salmonella microsome test assay of 300 chemicals. Proc Natl Acad Sci USA 72: 5135-5139.

  35. Zeiger E (1998) Identification of rodent carcinogens and noncarcinogens using genetictoxicity tests premises promises and performance. Regul Toxicol Pharmacol 28: 85-95.

  36. Moore MM, DeMarini DM, DeSerres FJ, Tindall KR (1997) Banbury Report Mammalian Cell Mutagenesis Cold Spring Harbor Laboratory, New York.

  37. Aaron CS, Bolcsfoldi G, Glatt HR, Moore M, Nishi Y, et al. (1994) Mammalian Cell Gene Mutation Assays Working Group Report. Mutation Res 312: 235-239.

  38. ECHA - European Chemicals Agency (2015) Guidance on Information Requirements and Chemical Safety Assessment. Chapter R.7a: Endpoint specific guidance. Version 3.1.

  39. (2014) OECD Guideline for the testing of chemicals Mammalian Bone Marrow Chromosomal Aberration.

  40. Adler ID (1984) Cytogenetic Tests in Mammals. In: Venittand S, Parry JM, Mutagenicity Testing: A Practical Approach. Washington DC, IRL Press, 275-306.

  41. Preston RJ, Dean BJ, Galloway S, Holden H, McFee AF, et al. (1987) Mammalian in vivo cytogenetic assays Analysis of chromosome aberrations in bone marrow cells. Mutat Res 189: 157-165.

  42. Richold M (1990) In Vivo Cytogenetics Assays. Basic Mutagenicity Tests: UKEMS Recommended Procedures: UKEMS Subcommittee on Guidelines for Mutagenicity Testing: Report, Part I revised. In: Kirkland DJ, Cambridge University Press, Cambridge, 115-141.

  43. Tice RR, Hayashi M, MacGregor JT, Anderson D, Blakey DH, et al. (1994) Report from the working group on the in vivo mammalian bone marrow chromosomal aberration test. Mutat Res 312: 305-312.

  44. (2014) OECD Guideline for the testing of chemicals. In vitro Mammalian Chromosome Aberrration Test.

  45. Doherty AT (2012) The in vitro micronucleus assay. Methods Mol Biol 817: 121-141.

  46. (2014) OECD Guideline for the testing of chemicals. Mammalian Erythrocyte Micronucleus Test.

  47. Hayashi M, MacGregor JT, Gatehouse DG, Blakey DH, Derfinger SD, et al. (2007) In vivo erythrocyte micronucleus assay III. Validation and regulatory acceptance of automated scoring and the use of rat peripheral blood reticulocytes, with discussion of non-hematopoietic target cells and a single dose-level limit test. Mutat Res 627: 10-30.

  48. (2014) OECD Guideline for the testing of chemicals. In vitro Mammalian Cell Micronucleus Test.

  49. (2014) OECD Guideline for the testing of chemicals Genetic Toxicology: DNA Damage and Repair Unscheduled DNA Synthesis in Mammalian Cells in vitro.

  50. (1997) OECD Guideline for the testing of chemicals. Unscheduled DNA Synthesis (UDS) Test with mammalian Liver Cells in vivo.

  51. (2016) OECD Guideline for the testing of chemicals. In Vivo Mammalian Alkaline Comet Assay.

  52. Dobrovolsky VN, Miura D, Heflich RH, Dertinger SD (2010) The in vivo Pig-a gene mutation assay a potential tool for regulatory safety assessment. Environ Mol Mutagen 51: 825-835.

  53. Fluckinger-Isler S, Baumeister M, Braun K, Gervais V, Hasler-Nguyen N, et al. (2004) Assessment of the performance of the Ames II assay: a collaborative study with 19 coded compounds. Mutation Research Genetic Toxicology and Environmental Mutagenesis 558: 181-197.

  54. Van Der Lelie D, Verschaeve L, Regniers L (2000) Corbisier P Use of bacterial tests (the VITOTOX® genotoxicity test and the BIOMET heavy metal test) to analyse chemicals and environmental samples. In: New MicroBiotests for Routine Toxicity Screening and Biomonitoring. 197-207.

  55. ICH S2 (R2) (2011) Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use. Step 5: EU: Adopted by CHMP, December 2011, issued as EMA/CHMP/ICH/126642/2008; MHLW, Federal Register, 77: 33748-33749.

  56. Kirkland D, Reeve L, Gatehouse D, Vanparys P (2011) A core in vitro genotoxicity battery comprising the Ames test plus the in vitro micronucleus test is sufcient to detect rodent carcinogens and in vivo genotoxins. Mutat Res 721: 27-73.

  57. Niemela JR, Wedebye EB, Nikolov NG, Jensen GE, Ringsted T, et al. (2010) The Advisory list for self-classification of dangerous substances. The Danish Environmental Protection Agency.

  58. Serafimova R, Gatnick F, Worth A (2010) Review of QSAR Models and Software Tools for Predicting of Genotoxicity and Carcinogenicity. Publications Office of the European Union.

  59. Hansen K, Mika S, Schroeter T, Sutter A, ter Laak A, et al. (2009) Benchmark data set for in silico prediction of Ames mutagenicity. J Chem Inf Model 49: 2077-2081.

  60. ICH M7 Genotoxic impurities (2014) Assessment and Control of DNA reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk.

  61. White AC, Mueller RA, Gallavan RH, Aaron S, Wilson AG (2003) A multiple in silico program approach for the prediction of mutagenicity from chemical structure. Mutat Res 539: 77-89.

  62. Jolly R, Ahmed KB, Zwickl C, Watson I, Gombar V (2015) An evaluation of in-house and off-the-shelf in silico models implications on guidance for mutagenicity assessment. Regul Toxicol Pharmacol 71: 388-397.

  63. Dobo KL, Greene N, Fred C, Glowienke S, Harvey JS, et al. (2012) In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities an industry survey. Regul Toxicol Pharmacol 62: 449-455.

  64. Gini G, Franchi AM, Manganaro A, Golbamaki A, Benfenati E (2014) ToxRead: a tool to assist in read across and its use to assess mutagenicity of chemicals. SAR QSAR Environ Res 25: 999-1011

  65. Benigni R, Bossa C (2008) Predictivity and reliability of QSAR Models the case of mutagens and carcinogens. Toxicol Mec Methods 18: 137-147.

  66. Valerio LG, Cross KP (2012) Characterization and validation of an in silico toxicology model to predict the mutagenic potential of drug impurities. Toxicol Appl Pharmacol 260: 209-221.

  67. Sutter A, Amberg A, Boyer S, Brigo A, Contrera JF, et al. (2013) Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. Regul Toxicol Pharmacol 67: 39-52.

  68. Cassano A, Raitano G, Mombelli E, Fernandez A, Cester J, et al. (2014) Evaluation of QSAR models for the prediction of Ames genotoxicity a retrospective exercise on the chemical substances registered under the EU REACH regulation. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 32: 273-298.

  69. Arvidson K, Rathman J, Volarath P, Mostrag A, Tarkhov A (2014) Evaluation of the chemical inventories in the US FDA's Office of Food Additive Safety for human health endpoints using a toxicity prediction system. U.S. FDA CFSAN Altamira LLC Molecular Networks GmbH Ohio State University, USA.

  70. Schwab CH, Rathman JF, Marusczyk J, Mostrag A, Bienfait B, et al. (2016) A reliable workflow for in silico assessment of genetic toxicity and application to pharmaceutical genotoxic impurities. SOT Abstract/Toxicology Letters 258: S54-S61.

  71. Papamokos G, Silins I (2016) Combining QSAR Modeling and Text-Mining Techniques to Link Chemical Structures and Carcinogenic Modes of Action. Front Pharmacol 7: 284.

  72. (2015) OECD Guideline for the testing of chemicals. In vitro Mammalian Gene Mutation Test using the Hprt and xprt genes.

  73. (2015) OECD Guideline for the testing of chemicals. In vitro Mammalian Gene Mutation Test using the Thymidine Kinase Gene.

  74. (2013) OECD Guideline for the testing of chemicals. Transgenic Rodent Somatic and Germ Cell Gene Mutation Assays.